UK firm to trial T-cell Covid vaccine that could give longer immunity

Posted by on November 14, 2021 7:01 pm
Categories: Global Stories

Exclusive: Oxfordshire-based Emergex gets go-ahead for trials in Switzerland for skin patch vaccine

An Oxfordshire-based company will soon start clinical trials of a second-generation vaccine against Covid-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.

Emergex was set up in Abingdon in 2016 to develop T-cell vaccines, the brainchild of Prof Thomas Rademacher, the firm’s chief executive and professor emeritus of molecular medicine at the University College London medical school.

Continue reading…

Leave a Reply

Your email address will not be published.